John P.H. Wilding
University College London Hospitals NHS Foundation Trust
2 papers in the Anchorcite directory, published between 2018 and 2021, cited 12,404 times in total.
ORCID profileResearch topics
- Diabetes Treatment and Management · 2 papers
- Chronic Kidney Disease and Diabetes · 1 paper
- Heart Failure Treatment and Management · 1 paper
- Pharmacology and Obesity Treatment · 1 paper
- Regulation of Appetite and Obesity · 1 paper
Frequent co-authors
- Stephen D. Wiviott · 1 paper
- Itamar Raz · 1 paper
- Marc P. Bonaca · 1 paper
- Ofri Mosenzon · 1 paper
- Eri Toda Kato · 1 paper
- Avivit Cahn · 1 paper
- Michael G. Silverman · 1 paper
- Thomas A. Zelniker · 1 paper
Papers
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine · 2018 · 6,600 citations
BACKGROUND: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS: of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes)…
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine · 2021 · 5,804 citations
BACKGROUND: Obesity is a global health challenge with few pharmacologic options. Whether adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 mg as an adjunct to lifestyle intervention has not been confirmed. METHODS: In…
Metadata from OpenAlex (CC0).